# ImmunoGen
 (stock symbol: IMGN) Logo in transparent PNG format

## ImmunoGen
 Logo large

### ImmunoGen
 Logo large Download PNG (32.85 KB)

![ImmunoGen
 Logo large Download PNG (32.85 KB)](/img/orig/IMGN_BIG-ca055fc9.png)

## ImmunoGen
 Logo icon format

### ImmunoGen
 Logo icon format Download PNG (27.13 KB)

![ImmunoGen
 Logo icon format Download PNG (27.13 KB)](/img/orig/IMGN-adc58a6f.png)

## About ImmunoGen


ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.

1. Website domain: immunogen.com
2. Employees: 106
3. Marketcap: $1.21 Billion USD


## Categories
- [x] ðŸ‡ºðŸ‡¸ United States
- [x] ðŸ’Š Pharmaceuticals
- [x] ðŸ§¬ Biotech
